Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC

(RARE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Ultragenyx: 3Q Earnings Snapshot

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/05/2018 | 04:17pm EDT

NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Monday reported a loss of $87.3 million in its third quarter.

On a per-share basis, the Novato, California-based company said it had a loss of $1.74.

The results topped Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for a loss of $1.94 per share.

The biotechnology company posted revenue of $11.8 million in the period, which also topped Street forecasts. Nine analysts surveyed by Zacks expected $11.2 million.

Ultragenyx shares have increased 14 percent since the beginning of the year. In the final minutes of trading on Monday, shares hit $53.10, a climb of 7 percent in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RARE at https://www.zacks.com/ap/RARE

Automated Insights, source Associated Press News

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ULTRAGENYX PHARMACEUTICAL
04/17ULTRAGENYX PHARMACEUTICAL INC. : Regulation FD Disclosure (form 8-K)
AQ
04/16ULTRAGENYX PHARMACEUTICAL : Announces UX007 Granted Fast Track Designation and R..
AQ
04/11Ultragenyx to Present Corporate Update at Analyst and Investor Day on April 1..
GL
03/27ULTRAGENYX PHARMACEUTICAL : Announces Approval of Crysvita in Brazil for the Tre..
AQ
03/26ULTRAGENYX PHARMACEUTICAL : Announces Approval of Crysvita® (burosumab) in Brazi..
AQ
03/01ULTRAGENYX PHARMACEUTICAL INC. : Entry into a Material Definitive Agreement, Fin..
AQ
03/01ULTRAGENYX PHARMACEUTICAL : Announces Pricing of Public Offering of Common Stock
AQ
02/26ULTRAGENYX PHARMACEUTICAL : Announces Pricing of Public Offering of Common Stock
AQ
02/26ULTRAGENYX PHARMACEUTICAL : Announces Proposed Public Offering of Common Stock
AQ
02/25Ultragenyx Announces Proposed Public Offering of Common Stock
GL
More news
Financials ($)
Sales 2019 105 M
EBIT 2019 -356 M
Net income 2019 -345 M
Finance 2019 214 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 35,0x
EV / Sales 2020 16,7x
Capitalization 3 887 M
Chart ULTRAGENYX PHARMACEUTICAL INC
Duration : Period :
Ultragenyx Pharmaceutical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL
Short TermMid-TermLong Term
TrendsBearishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 74,2 $
Spread / Average Target 9,5%
EPS Revisions
Managers
NameTitle
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Wladimir Hogenhuis Chief Operating Officer
Shalini Sharp Chief Financial Officer & Executive Vice President
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Sector and Competitors
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC57.84%3 887
GILEAD SCIENCES2.54%80 369
VERTEX PHARMACEUTICALS5.37%44 835
REGENERON PHARMACEUTICALS-6.29%36 949
GENMAB4.82%10 352
SAREPTA THERAPEUTICS INC10.16%8 700